Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$3.09 - $7.46 $154 - $373
50 Added 0.19%
26,750 $84,000
Q1 2022

May 13, 2022

SELL
$5.07 - $7.2 $2,028 - $2,880
-400 Reduced 1.48%
26,700 $160,000
Q4 2021

Feb 09, 2022

BUY
$5.67 - $8.54 $62,370 - $93,939
11,000 Added 68.32%
27,100 $174,000
Q3 2021

Nov 12, 2021

BUY
$13.4 - $16.3 $36,180 - $44,010
2,700 Added 20.15%
16,100 $222,000
Q2 2021

Aug 11, 2021

BUY
$14.81 - $19.13 $37,025 - $47,825
2,500 Added 22.94%
13,400 $199,000
Q1 2021

May 13, 2021

SELL
$14.52 - $23.53 $68,244 - $110,591
-4,700 Reduced 30.13%
10,900 $194,000
Q4 2020

Feb 11, 2021

BUY
$10.14 - $15.19 $25,350 - $37,975
2,500 Added 19.08%
15,600 $223,000
Q3 2020

Nov 12, 2020

BUY
$9.57 - $21.32 $8,613 - $19,188
900 Added 7.38%
13,100 $132,000
Q2 2020

Aug 14, 2020

BUY
$12.21 - $16.99 $148,962 - $207,277
12,200 New
12,200 $172,000
Q1 2020

May 14, 2020

SELL
$9.03 - $19.72 $110,165 - $240,584
-12,200 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$13.01 - $17.15 $158,722 - $209,229
12,200 New
12,200 $172,000
Q1 2019

May 14, 2019

SELL
$11.65 - $17.72 $966,530 - $1.47 Million
-82,964 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$10.72 - $16.73 $255,607 - $398,910
23,844 Added 40.33%
82,964 $924,000
Q3 2018

Nov 13, 2018

SELL
$17.73 - $26.69 $145,279 - $218,697
-8,194 Reduced 12.17%
59,120 $825,000
Q2 2018

Aug 13, 2018

SELL
$10.79 - $24.44 $411,487 - $932,043
-38,136 Reduced 36.17%
67,314 $1.22 Million
Q1 2018

May 14, 2018

BUY
$9.0 - $20.16 $388,386 - $869,984
43,154 Added 69.27%
105,450 $1.18 Million
Q4 2017

Feb 09, 2018

BUY
$13.26 - $22.86 $68,302 - $117,751
5,151 Added 9.01%
62,296 $1.21 Million
Q3 2017

Nov 14, 2017

SELL
$19.76 - $24.9 $216,233 - $272,480
-10,943 Reduced 16.07%
57,145 $1.24 Million
Q2 2017

Aug 14, 2017

BUY
N/A
68,088
68,088 $1.36 Million

Others Institutions Holding OMER

About OMEROS CORP


  • Ticker OMER
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,730,000
  • Market Cap $620M
  • Description
  • Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical program...
More about OMER
Track This Portfolio

Track Baird Financial Group, Inc. Portfolio

Follow Baird Financial Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baird Financial Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Baird Financial Group, Inc. with notifications on news.